Abivax 9-month Net Loss Widens On Higher R&D Costs, Lower Operating Income

Abivax reported a widened nine-month net loss of €254.1m versus €136.9m a year earlier, driven by higher R&D spending (€133.4m from €107.9m) and a larger financial loss (€79.7m vs €6.7m), leaving operating loss at €174.4m as operating income fell to €4.1m. The R&D increase reflects costs for its lead candidate obefazimod across Phase 3 ulcerative colitis and Crohn’s disease programs; top-line 8‑week induction results were released in Q3 2025 and 44‑week maintenance data are due in Q2 2026. Management plans to prepay Kreos/Claret Tranches B and C by Dec. 31, 2025 and says €589.7m of cash will fund operations through Q4 2027; shares fell about 6% on the update, underscoring investor sensitivity to near-term burn despite a multi-year runway and upcoming clinical catalysts.

Analysis

Abivax reported a widened nine-month net loss of €254.1 million versus €136.9 million a year earlier, driven by higher R&D spending of €133.4 million (up from €107.9 million) and a markedly larger financial loss of €79.7 million versus €6.7 million. Operating loss widened to €174.4 million from €130.2 million while operating income fell to €4.1 million from €8.1 million, and the stock reacted with a 6.08% intraday decline to $117.91.

The R&D increase is specifically linked to costs for obefazimod across Phase 3 ulcerative colitis (UC) trials and Crohn’s disease (CD) programs, with top-line 8-week induction results reported in Q3 2025 and a key 44-week maintenance data readout expected in Q2 2026; these clinical milestones remain the primary value drivers. Additional spend relates to Phase 2b CD trials and other obefazimod studies, indicating management is prioritizing late-stage development over near-term profitability.

Management says cash and cash equivalents of €589.7 million are sufficient to fund forecasted cash flows through Q4 2027 and has notified bondholders of intent to prepay Kreos/Claret Tranches B and C with a transaction expected to close on December 31, 2025, which will be a meaningful cash outflow. The surge in non‑operating losses and the planned prepayment create near‑term balance sheet and liquidity considerations despite the stated runway, supporting the moderately negative market sentiment and the 0.35 market impact score.

Key Decisions for Investors

• Treat the Q2 2026 44-week maintenance readout for obefazimod as the primary binary catalyst and consider reducing incremental exposure ahead of the announcement or using event-driven hedges,
• Reassess position size given the widened net loss and higher R&D burn; it may be prudent to trim holdings or hedge until the company clarifies the drivers of the €79.7m financial loss,
• In valuation and liquidity models, incorporate the €589.7m cash runway through Q4 2027 and the planned Kreos/Claret prepayment by Dec 31, 2025 as near-term cash uses that reduce optionality,
• For investors with a higher risk tolerance, maintain a smaller speculative stake to capture upside from successful Phase 3/maintenance data while keeping exposure limited to capital you can afford to lose